Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis


Abstract

Background—The role of inhaled corticosteroids in the long term management of chronic obstructive pulmonary disease (COPD) is still unclear. A meta-analysis of the original data sets of the randomised controlled trials published thus far was therefore performed. The main question was: “Are inhaled corticosteroids able to slow down the decline in lung function (FEV1) in COPD?”

Methods—A Medline search of papers published between 1983 and 1996 was performed and three studies were selected, two of which were published in full and one in abstract form. Patients with “asthmatic features” were excluded from the original data. Ninety five of the original 140 patients treated with inhaled corticosteroids (81 with 1500 µg beclomethasone daily, six with 1600 µg budesonide daily, and eight with 800 µg beclomethasone daily) and 88 patients treated with placebo (of the initial 144 patients) were included in the analysis. The effect on FEV1 was assessed by a multiple repeated measurement technique in which points of time in the study and treatment effects (inhaled corticosteroids compared with placebo) were investigated.

Results—No baseline differences were observed (mean age 61 years, mean FEV1 45% predicted). The estimated two year difference in prebronchodilator FEV1 was +0.034 l/year (95% confidence interval (CI) 0.005 to 0.063) in the inhaled corticosteroid group compared with placebo. The postbronchodilator FEV1 showed a difference of +0.039 l/year (95% CI –0.006 to 0.084). No beneficial effect was observed on the exacerbation rate. Worsening of the disease was the reason for drop out in four patients in the treatment group compared with nine in the placebo group. In the treatment group six of the 95 subjects dropped out because of an adverse effect which may have been related to the treatment compared with two of the 88 patients in the placebo group.

Conclusions—This meta-analysis in patients with clearly defined moderately severe COPD showed a beneficial course of FEV1, during two years of treatment with relatively high daily dosages of inhaled corticosteroids.

(Keywords: chronic obstructive pulmonary disease; inhaled corticosteroids)

The role of anti-inflammatory therapy (inhaled corticosteroids) is still unclear in the management of patients with stable chronic obstructive pulmonary disease (COPD). In contrast to asthma, several international consensus reports on the management of COPD mention that the evidence for beneficial effects of inhaled corticosteroids on lung function and symptoms has not yet been established. In asthma, inhaled corticosteroids have beneficial effects by reducing inflammation in the airways. Although inflammation seems to be present in the airway walls of patients with COPD (in terms of macrophages, T cells, and neutrophils), the specific immunopathology is thought to be different from asthma. Short term treatment with both inhaled and systemic corticosteroids may have some beneficial effects on symptoms and lung function in subgroups of COPD patients, in particular those with partially reversible airways obstruction. Two long term uncontrolled and retrospective studies have shown that systemic corticosteroids slowed down the progression of decline in lung function in patients with moderate and severe COPD. The effects of prednisone were observed after 6–24 months, the effects being larger with doses of 10 mg and higher. Especially in the long term, however, systemic corticosteroids may cause serious side effects. If long term treatment with corticosteroids is needed, it would therefore be preferable to replace systemic by inhaled corticosteroids.

Thus far, three long term prospective clinical trials on inhaled corticosteroids in COPD have been published in full and two in abstract form. All studies showed more or
less beneficial effects of inhaled corticosteroids on the decline in lung function. In two of these studies it was shown that patients with “asthma features”—that is, high bronchodilator response and bronchial responsiveness—may respond better to inhaled corticosteroids. However, the inclusion of “asthmatic” COPD patients in each of these studies may have caused an overestimation of the beneficial effects of inhaled corticosteroids. It would be interesting to re-analyse the effects of inhaled corticosteroids only in the patients with clearly defined COPD, preferably by a cumulative analysis in order to avoid, as far as possible, underestimations of the effects of inhaled corticosteroids by subgroup analysis of each separate study.

We have therefore performed a meta-analysis of the original individual patient data from these studies, selecting only patients with a strict diagnosis of COPD. The primary question was: “Are inhaled corticosteroids able to slow down the decline in lung function?” Secondary questions were: “What is the point in time when inhaled corticosteroids start to have a significant effect on the course of lung function?” “Is there a dose-effect relationship?” and “Which clinical characteristics predict the effect?”

**Methods**

**SELECTION OF STUDIES FOR THE META-ANALYSIS**

A Medline search covering the period from 1983 to 1996 with the “free text” words “COPD”, “chronic airflow obstruction”, “obstructive airways disease”, “chronic airflow limitation”, “chronic bronchitis”, “inhaled corticosteroids”, “beclomethasone”, “budesonide”, and “fluticasone” yielded 94 references. The reference list of these studies was also checked for usable studies. We also checked Biosis (1991–1996), Online Contents (1993–1996), “GLIN” (Grey Literature Netherlands, 1982–1996), The Cochrane Library, and Embase (1993–1996). No new references were found using the keywords above. Only studies with a duration of at least 24 months were considered to be long enough to assess the long term effects of inhaled corticosteroids on the decline in lung function. Only five studies met this criterion. Three studies were published in full and two as abstracts. In order to be able to compare the effect of inhaled corticosteroids with that of placebo, only randomised, placebo controlled clinical trials were included. Therefore, the self-controlled study of Dompeling et al and the therapeutic trial of Weir et al were not used in the meta-analysis.

**DETAILS OF THE STUDIES**

In table 1 patient selection criteria, method, and analysis of the three studies are summarised. Renkema et al investigated the effects of two years of treatment with inhaled budesonide (1600 µg/day) versus inhaled budesonide plus prednisone (5 mg/day) versus placebo on decline in lung function, symptoms, exacerbations, and drop outs in 58 non-allergic patients with moderate to severe COPD. In the French multicentre study by Derenne et al the effects of inhaled beclomethasone (1500 µg/day) versus placebo on lung function level and the duration of exacerbations were assessed during two years in 194 patients with moderate to severe COPD. Kerstjens et al investigated the effects of 800 µg inhaled beclomethasone and placebo on lung function level and decline and bronchial responsiveness during 30 months in a group of 274 patients with moderate asthma or COPD. A subgroup analysis was performed in 51 patients with a symptom based diagnosis of COPD.

**SELECTION OF PATIENTS FOR THE META-ANALYSIS**

In order to be able to exclude patients with “asthma features” in the analyses and also to maximise the contribution of individual patient data, we used the original clinical data.

Firstly, rigid diagnostic criteria were framed based on the most recent guidelines on COPD. The protocols and data bases of the three studies concerned were then collected. Thirdly, the investigators of the studies were sent an output of the baseline characteristics and follow up data of their own study in order to avoid misinterpretations of their study data.

**Inclusion criteria for individual patients in the meta-analysis**

1. Pulmonary symptoms compatible with the diagnosis of COPD (chronic breathlessness especially on exertion and/or (productive) cough during ≥3 months per year in two successive years).
2. Age 40 and over.
3. FEV1, following treatment with β2 agonist (≥400 µg salbutamol or ≥500 µg terbutaline) <FEV1 predicted –1.64SD.
4. Bronchodilator response to β2 agonist (≥400 µg salbutamol or ≥500 µg terbutaline) ≤9% of FEV1 predicted.
5. Previous or current smoker.

**Exclusion criteria for individual patients in the meta-analysis**

1. α1-Antitrypsin deficiency.
2. History of asthma.

**EFFECT PARAMETERS FOR THE META-ANALYSIS**

The primary effect parameter was prebronchodilator decline in FEV1, measured at two monthly or three monthly intervals according to the recommendations of the ERS. All FEV1 measurements were made in a stable state—that is, in the absence of an exacerbation.

The secondary effect parameters were postbronchodilator decline in FEV1, the number of drop outs, and the number of exacerbations. FEV1, after inhalation of ipratropium bromide was not assessed in all studies so only post-β2 agonist FEV1 values were used. In two studies FEV1, following treatment with β2 agonist was only assessed annually and in one study six monthly. In the study by Kerstjens et al a higher dose of β2 agonist was used (1 mg terbutaline) than in the other studies (500 µg terbutaline 3 and 400 µg salbutamol). Because of these differences within the studies in...
frequency, dosage, and type of bronchodilator used to measure postbronchodilator FEV₁, the prebronchodilator but not the postbronchodilator FEV₁, was used as the primary effect parameter in the meta-analysis.

In all three studies the number of drop outs and the reasons for drop out were recorded. The reasons for drop out were divided into “worsening of disease”, “adverse effects”, and “other” (personal reasons, unspecified reasons).

The number of exacerbations was recorded in all three studies. An exacerbation was defined similarly—that is, a doctor’s diagnosis of increasing respiratory symptoms requiring a short course of systemic corticosteroids and/or antibiotics.

Bronchial hyperresponsiveness was not used as a dependent variable or as a determinant of corticosteroid response because this clinical characteristic was not assessed in all studies. Also symptoms were not used as dependent variables because of too large variations in registration between the studies.

### META-ANALYSIS

The continuous variables were age, height, FEV₁, (litres), FEV₁/IVC, (%) as a dependent variable or as a determinant of corticosteroids in COPD. The effects of inhaled corticosteroids. The continuously measured variables were FEV₁, (litres), FEV₁ (expressed as a percentage of FEV₁ predicted), FEV₁/IVC, (%) and airway reversibility (bronchodilator response to β₂ agonist expressed as a percentage of FEV₁ predicted). Smoking history (number of pack years (cigarettes/day × years smoked divided by 20)), number of cigarettes/day, and allergy (total IgE, expressed as IU/ml). Dichotomous variables were sex, smoker (current/ex), regular use of anticholinergics, β₂ agonists, theophylline, mucolytics or almitrine (Victorion, a respiratory stimulant).

### Table 1

<table>
<thead>
<tr>
<th>Renkema et al</th>
<th>Derenne et al</th>
<th>Kerstjens et al (subgroup)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inclusion criteria</strong></td>
<td>Clinical diagnosis of COPD based on history (persistent dyspnoea without sudden attacks of dyspnoea; FEV₁ &lt; 80% pred; RV &gt; 100% pred; specific compliance (Cₑ₅) &gt; 100% pred after bronchodilatation; no signs of allergy (negative skin test results), total serum IgE &lt; 200 IU/ml, eosinophils in peripheral blood &lt; 250 × 10³/ml; stable phase of disease; η₁-antitrypsin within normal range; (ex-)smoker</td>
<td>Age ≤ 75; “chronic bronchitis”; FEV₁ &lt; 60–90% predicted; retFEV₁ &lt; 80% predicted; PaO₂ &lt; 55 mm Hg; usual treatment without corticosteroid; no exacerbation in the last three months; written informed consent</td>
</tr>
<tr>
<td><strong>Exclusion criteria</strong></td>
<td>Age &gt; 70; continuous corticosteroid therapy; severe concomitant disease</td>
<td>Other pulmonary diseases; corticosteroids past 15 days; unable to follow protocol; pregnant or lactating women; stomach ulcer without treatment; pulmonary tuberculosis; IgE &gt; 200 IU/ml and eosinophils &gt; 500 × 10³/ml</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>Clinical, one centre</td>
<td>Clinical, multicentre</td>
</tr>
<tr>
<td><strong>Design</strong></td>
<td>Double blind, placebo controlled, 3 parallel arms</td>
<td>Double blind, placebo controlled, 2 parallel arms</td>
</tr>
<tr>
<td><strong>Duration of study</strong></td>
<td>24 months</td>
<td>24 months</td>
</tr>
<tr>
<td><strong>Study drugs</strong></td>
<td>Bud 800 µg bd MDI through Nebuhaler® + plac 1 cc versus bud 800 µg bd + pred 5 mg 1/2 d versus plac bd + plac 1 cc</td>
<td>Bec 1500 µg MDI versus plac 1800 µg MDI</td>
</tr>
<tr>
<td><strong>Concomitant drugs</strong></td>
<td>Anticholinergics, β₂ agonists, theophylline or antihistamines</td>
<td>Anticholinergics, β₂ agonists, theophylline, mucolytics, almitrine</td>
</tr>
<tr>
<td><strong>Outcome</strong></td>
<td>FEV₁, decline; symptoms; duration of exacerbations</td>
<td>FEV₁, level of PEF, duration of corticosteroid course</td>
</tr>
<tr>
<td><strong>Criterium pulmonary dropout</strong></td>
<td>≥ 3 exacerbations within 3 consecutive months; severe progressive deterioration of lung function level</td>
<td>Insufficient effectiveness</td>
</tr>
<tr>
<td><strong>Definition exacerbation</strong></td>
<td>Increased complaints of dyspnoea and/or cough and/or purulent sputum (out) fever</td>
<td>(1) Increase in dyspnoea and/or (2) purulent sputum and fever</td>
</tr>
<tr>
<td><strong>Treatment of exacerbation</strong></td>
<td>7 days pred (35–30–25 mg etc), and a course of antibiotics if necessary</td>
<td>(1) Course of pred and/or (2) course of antibiotics &lt; 15 days</td>
</tr>
<tr>
<td><strong>Method of allergy measurement</strong></td>
<td>Skin tests, serum IgE, eosinophil count</td>
<td>Serum IgE and eosinophil count</td>
</tr>
<tr>
<td><strong>Compliance check</strong></td>
<td>Weighing canisters; counting tablets</td>
<td>Verbal check</td>
</tr>
<tr>
<td><strong>Overall method</strong></td>
<td>Explanatory analysis of variance</td>
<td>Repeated measurement analysis, explanatory analysis</td>
</tr>
<tr>
<td><strong>Subgroup</strong></td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td><strong>Measurement of FEV₁, decline</strong></td>
<td>Linear regression, ≥ 3 measurements needed</td>
<td>Repeated measurement</td>
</tr>
</tbody>
</table>
| **Financial support** | Astra Pharmaceuticals | GlaxoWellcome Inc. | Netherlands Health Research Promotion Program (SBO); Pharmaceutical companies: Astra Pharmaceuticals, Boehringer Ingelheim, Glaxo
patients in the study by Kerstjens et al who were treated with ipratropium bromide were considered as a placebo group since no long term effects other than the acute bronchodilatating effect of ipratropium bromide were observed. Since the duration of the study by Kerstjens et al was 30 months and the two other studies took 24 months, only patient data up to 24 months of study were used.

In the study by Renkema et al two monthly FEV1 measurements were performed compared with three monthly measurements in the two other studies. In all the analyses the average individual FEV1 values of the measurements of 2 and 4, 8 and 10, 14 and 16, and 20 and 22 months were therefore used as estimates for the FEV1 at 3, 9, 15 and 21 months, respectively. Differences in drop out percentages and reasons for drop out during the trial between the inhaled corticosteroid and the placebo groups were tested with the χ2 test. Differences in the number of exacerbations per year between both groups were tested univariately with the Student’s t test.

The effect of inhaled corticosteroids (independent of the dose) on prebronchodilator and postbronchodilator FEV1 (litres) was measured with a multiple repeated measurement technique in which patient and time effects on FEV1 were separately investigated in an intention-to-treat analysis. Preliminary analysis demonstrated no measurement*treatment interaction. For that reason a random coefficient model was chosen in which all available individual time points of FEV1, measurements were incorporated and analysed. In a first model the effect of inhaled corticosteroids, irrespective of the dose used, on the course of FEV1 was compared with placebo. In a second analysis the dose effects of the inhaled corticosteroid (800 µg beclomethasone (“low dose”) versus 1500 µg beclomethasone or 1600 µg budesonide (“high dose”)) on the course of FEV1 were investigated by adding one dummy.

In order to correct for possible confounders and to be able to assess which clinical characteristics may predict the influence of inhaled corticosteroids on the change in FEV1, the baseline variables of age, height, sex, FEV1, airway reversibility, pack years, smoking, IgE, anticholinergics, β2 agonists, theophylline, mucolytics, and almitrine were introduced into the model. The number of exacerbations during the study was also introduced into the model. In addition, data on the number of cigarettes smoked daily during the study (assessed at each visit) were incorporated into the analysis at each time point of measurement. Only baseline data of the number of cigarettes smoked daily were available from the study of Renkema et al. However, smoking behaviour was shown to be remarkably constant during the study. Compliance rates and a complete registration of all adverse effects during the studies were not available for all three studies.

First, all possible interaction terms of the independent variables with treatment were incorporated into the model. Secondly, in a backwards procedure variables with the highest

### Table 3 Mean (SD) baseline characteristics and exacerbation and drop out rates of patients using inhaled corticosteroids (irrespective of the dose) or placebo

<table>
<thead>
<tr>
<th></th>
<th>Inhaled corticosteroids (n = 95)</th>
<th>Placebo (n = 88)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>61 (7)</td>
<td>61 (7)</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>170 (7)</td>
<td>168 (7)</td>
</tr>
<tr>
<td>Male (%)</td>
<td>89 (9)</td>
<td>79 (9)</td>
</tr>
<tr>
<td>FEV1 (l)</td>
<td>1.42 (0.47)</td>
<td>1.30 (0.38)</td>
</tr>
<tr>
<td>FEV1 (% pred)</td>
<td>46 (11)</td>
<td>44 (11)</td>
</tr>
<tr>
<td>FEV1/IVC (%)</td>
<td>49 (13)</td>
<td>47 (11)</td>
</tr>
<tr>
<td>Airway reversibility (% of FEV1 pred)</td>
<td>3.2 (2.7)</td>
<td>2.9 (2.5)</td>
</tr>
<tr>
<td>Pack years</td>
<td>40 (25)</td>
<td>43 (24)</td>
</tr>
<tr>
<td>Smoker (current/ex)</td>
<td>32/63</td>
<td>34/54</td>
</tr>
<tr>
<td>Cigarettes/day (n)</td>
<td>17 (12)</td>
<td>17 (11)</td>
</tr>
<tr>
<td>Log10(IgE+1) (RU/ml)</td>
<td>1.71 (0.59)</td>
<td>1.67 (0.50)</td>
</tr>
</tbody>
</table>

**Regular use of (% of patients):**
- Anticholinergics: 25/32
- Short acting β2 agonists: 60/62
- Theophylline: 56/53
- Mucolytics: 33/40
- Almitrine: 10/13

**During the study:**
- Exacerbations/year: 0.9 (0.9) vs 1.0 (1.3)
- Drop outs (n): 35 vs 29
- Reason for drop out (n):
  - Worsening of the disease: 4 vs 9
  - Adverse effects: 17 vs 12
  - Other reasons: 14 vs 8

---

![Figure 1 Course of prebronchodilator FEV1 in the inhaled corticosteroid and placebo groups. SE values and numbers of subjects participating in the study at each point of measurement are presented.](http://thorax.bmj.com/ on June 23, 2017 - Published by group.bmj.com)
Table 4 Influence of inhaled corticosteroids compared with placebo on the change in prebronchodilator and postbronchodilator FEV1 (l) by repeated measurement analysis. The model presents only variables with p<0.05

<table>
<thead>
<tr>
<th>Subject</th>
<th>Two-year estimate (l/year)</th>
<th>SE</th>
<th>p value (Pr&gt;F)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prebronchodilator: Treatment effect (inhaled corticosteroids versus placebo (n = 183))</td>
<td>+0.034</td>
<td>0.015</td>
<td>0.026</td>
</tr>
<tr>
<td>FEV1, baseline (l)</td>
<td>+0.97</td>
<td>0.027</td>
<td>0.0001</td>
</tr>
<tr>
<td>Almitrine (yes)</td>
<td>+0.063</td>
<td>0.025</td>
<td>0.012</td>
</tr>
<tr>
<td>Postbronchodilator: Treatment effect (inhaled corticosteroids versus placebo, n = 183)</td>
<td>+0.039</td>
<td>0.023</td>
<td>0.095</td>
</tr>
<tr>
<td>Height (m)</td>
<td>+0.64</td>
<td>0.222</td>
<td>0.004</td>
</tr>
<tr>
<td>Reversibility FEV1 (as % of predicted FEV1)</td>
<td>+0.014</td>
<td>0.005</td>
<td>0.003</td>
</tr>
<tr>
<td>FEV1, baseline (l)</td>
<td>+0.92</td>
<td>0.036</td>
<td>0.0001</td>
</tr>
<tr>
<td>β2 agonists (yes)</td>
<td>+0.058</td>
<td>0.027</td>
<td>0.034</td>
</tr>
</tbody>
</table>

p value were subsequently deleted until only variables with p<0.05 remained.

No analysis was performed with linear regression based measurement of FEV1 decline. Preliminary analysis demonstrated a non-linear course in the FEV1; the explained variance of individual linear regression analysis of FEV1 was only 24% on average (SD 24%, range 0–99%).

Results

Subject Selection

The selection procedures of subjects for the meta-analysis are presented in table 2. The most important reasons for exclusion were “mild obstruction” (FEV1 ≥ FEV1 predicted –1.64 SD, 42 of original 303 patients) or “reversible obstruction” (>9% of the FEV1 predicted, 53 of 303 patients). Twenty eight of the 58 subjects (48%) in the study by Renkema et al were excluded from the meta-analysis, 15 because of reversible obstruction. From the study by Derenne et al 42 (17%) of the 194 patients were excluded from the meta-analysis, 21 because they were never-smokers. Subjects in the study by Kerstjens et al were younger and had less severe airway obstruction than in the other two studies. Therefore, only 15 (29%) of the 51 subjects in this study were eligible for the meta-analysis. Within each study the baseline characteristics between the patients in the inhaled corticosteroid group and the placebo group eligible for the meta-analysis did not differ significantly in all relevant parameters.

Baseline Data

Table 3 shows the combined baseline characteristics of the 183 subjects selected. No statistically significant differences between the inhaled corticosteroid group and the placebo group were present in the relevant parameters.

Effects of Inhaled Corticosteroids on FEV1 (Repeated Measurement Analysis)

In fig 1 the effect of two years of treatment with inhaled corticosteroids, irrespective of their dose, on the prebronchodilator FEV1, is presented versus placebo, and in table 4 the results are presented after adjustment of variables with p<0.05. The estimate was +0.034 l/year (95% confidence interval (CI) 0.005 to 0.063), which was statistically significant (p = 0.026). If the dose of inhaled corticosteroids was included in the model, the estimate was +0.002 l/year (95% CI –0.061 to 0.065) for the low dose of inhaled corticosteroids and +0.039 l/year (95% CI 0.008 to 0.070) for the high dose (p = 0.043).

The same procedure with postbronchodilator FEV1 showed a two year treatment effect for the inhaled corticosteroid group versus the placebo group of +0.039 l/year (95% CI –0.006 l to 0.084 l, p = 0.095) (table 4, fig 2), which was maintained only in the high dose group if the dose of inhaled corticosteroids was taken into account.

Determinants of Lung Function Slope and Corticosteroid Response

Table 4 shows an independent effect of the following two variables on a beneficial course in FEV1: the use of short acting β2 agonists and a higher baseline FEV1. No interaction of any of the variables analysed with the inhaled corticosteroid treatment was observed.

Effect of Inhaled Corticosteroids on Exacerbations and Drop Outs

During the study the mean (SD) number of exacerbations per year was 0.9 (0.9) in the inhaled corticosteroid group and 1.0 (1.3) in the placebo group (p>0.05; table 3). The drop out rate during the study was 36% in the inhaled corticosteroid group and 32% in the placebo group (table 3). In the placebo group twice as many patients dropped out due to worsening of the disease compared with the actively treated group (9/88 versus 4/95 patients, p = 0.11). No patients dropped out in the low dose inhaled corticosteroid group. Comparison of the baseline characteristics between those who fulfilled the protocol and the drop outs within each trial group showed no indications of selective drop out or “survivor effect”.

Adverse Effects

In the inhaled corticosteroid group 17 of the 95 subjects dropped out because of adverse effects...
compared with 12 of 88 in the placebo group ($\chi^2 = 0.62, p = 0.43$). All these drop outs were in the study by Derenne et al. An additional investigation of the adverse effect files of these patients showed that in six of the 95 subjects in the active group the adverse event leading to drop out may have been related to the treatment (cough, dysphonia, sore throat, anorexia, problems with taste and the nasal organ, and headache). In the placebo group the cause of drop out in two of the 88 subjects could have been related to treatment (cough, dysphonia, sore throat) ($\chi^2 = 1.78, p = 0.18$). No serious adverse effects related to the treatment occurred.

**Discussion**

We combined the original data of three published long term intervention studies with inhaled corticosteroids in moderately severe COPD, selecting only patients with clearly defined disease. The meta-analysis showed a significant beneficial effect of inhaled corticosteroids compared with placebo on the course of the prebronchodilator FEV$_1$ during two years of treatment (+0.068 l), whereas only a tendency towards an effect of inhaled corticosteroids on postbronchodilator FEV$_1$ was shown. However, the latter results pertain to only three data points. A specific measurement*treatment effect was lacking. A daily dose of 1500/1600 µg of the inhaled corticosteroid was more effective than 800 µg, although it should be noted that only a small number of subjects received the lower dose. No beneficial effect was observed on the exacerbation rate or drop out rate. Finally, no interaction effect of the variables assessed on the response to inhaled corticosteroids was found.

When the three original studies contributing to the meta-analysis were considered, no heterogeneity was seen in the beneficial effect of inhaled corticosteroids on the FEV$_1$. Renkema et al demonstrated a median decline of FEV$_1$ of 60 ml/year in the placebo group and 30 ml/year in the budesonide group. Due to large interpatient variations this difference was not significant. Kerstjens et al found the FEV$_1$ to increase significantly by +7.4 (3.1)% predicted in the beclomethasone group compared with the placebo group after the first six months of study. The study by Derenne et al demonstrated an improvement in FEV$_1$, of +1.44% from baseline in the experimental group compared with –0.62% in the placebo group (p = 0.05) during the two year study. Subjects of these three studies who were excluded from our meta-analysis were patients who had features of asthma in addition to COPD. An interesting finding was that, although we selected only patients with clearly defined COPD for the analysis, a beneficial effect of inhaled corticosteroids on the course of FEV$_1$ remained present.

Several shortcomings of the study should be mentioned. Firstly, we presented the results of a “re-analysis” using studies with a duration of only two years. Secondly, compliance data and the doses of concomitant drugs were not incorporated and corrected for in the analysis. Thirdly, cost effectiveness was only assessed in the study by Kerstjens. Rutten-van Mólk et al found that “addition of an inhaled corticosteroid to a β agonist leads to significant benefits in respiratory function and restricted activity days with relatively low additional health care costs”. However, an interaction analysis in this study showed that inhaled corticosteroids were most beneficial in patients with the “classic” asthma profile (allergy, reversibility, non-smoking, and mostly young). Longer term and larger studies with more detailed registration of compliance, drug use during the trial, and cost effectiveness are therefore required to confirm the conclusions of our study.

In two retrospective studies with oral prednisone in a group of patients with moderate and severe COPD it has been suggested that the time to reach a response to oral corticosteroids is 6–24 months. In our meta-analysis with inhaled corticosteroids no specific time point of response was observed, but a sustained effect of inhaled corticosteroids on the course of FEV$_1$ took place during the two years. In a self-controlled study in 26 patients with moderate COPD Dompeling et al investigated the effects of 800 µg beclomethasone on the course of FEV$_1$. The prebronchodilator FEV$_1$ increased during the first six months of the trial with no further effect on the decline in FEV$_1$ after that. The study by Kerstjens et al showed that a response had already been achieved after three months. In both studies inclusion of COPD patients with some “asthmatic features” such as airway reversibility and allergy in both studies might have contributed to this early response. Preliminary results of the EUROSCOP study, a large three year study in patients with mild COPD using 800 µg budesonide, have also shown an effect of inhaled corticosteroids, especially during the first three months of the study (oral presentation, Congress of the European Respiratory Society, 1997). Further analysis is needed to show whether this early effect of inhaled corticosteroids may indicate “asthmatic features” in the group of patients with COPD selected. Moreover, in the light of the previous studies by Postma et al with systemic corticosteroids, the delay in reaching “the response” in our study may suggest a true effect of inhaled corticosteroids on COPD.

The course of postbronchodilator FEV$_1$, tended to differ from prebronchodilator FEV$_1$, especially after one year and to the advantage of the placebo group. In fig 2 it appears that the FEV$_1$ in the placebo group increased considerably after one year of the study. This may be explained partly by the fact that “all” participants (including drop outs) were plotted. The drop outs in the placebo group, most of which dropped out during the first year of the study, had a lower baseline FEV$_1$, % predicted than those who fulfilled the protocol of the placebo group (41% versus 47% of FEV$_1$, predicted, p<0.0174). It was shown that the course of postbronchodilator FEV$_1$, in patients in the
Long term effects of inhaled corticosteroids in COPD

placebo group who finished the study was reasonably stable during the first year of the study.
A daily dose of 1500 µg beclomethasone or 1600 µg budesonide was more effective than 800 µg beclomethasone, with effects on the prebronchodilator FEV₁ of 0.039 l/year and 0.002 l/year, respectively. However, in the analysis the group of patients treated with 800 µg beclomethasone was relatively small (n = 8) and therefore this result has to be interpreted with great caution. On the other hand, in short term studies with inhaled corticosteroids in patients with moderately severe COPD daily dosages of at least 1500 µg seemed to be necessary to achieve significant improvements in FEV₁. Watson et al found no beneficial effects on the level of lung function in a nine month single blind follow up study with 1200 µg budesonide daily. In a long term therapeutic trial (mean duration 26 months) of oral and inhaled corticosteroids in 121 patients with non-asthmatic chronic airway obstruction, beclomethasone 750 µg twice daily seemed to slow down the decline in FEV₁. Unfortunately this study was not placebo controlled and is only published in abstract form. In patients with moderate asthma daily doses of 800 µg inhaled corticosteroids are often sufficient to achieve disease control. In the light of our study we hypothesise that, in patients with moderate to severe COPD, differences in the type and site of inflammation in asthma and COPD might lead to the need for higher dosages of inhaled corticosteroids in COPD. In COPD the largely neutrophilic and lymphocytic inflammation seems to take place in the peripheral airways while in asthma the predominantly eosinophilic inflammation is located mainly in the central airways. These two considerations might explain the need for a higher dosage of inhaled corticosteroids in moderate to severe COPD compared with moderate asthma. If we consider the preliminary results of the EUROSCOP, the dosage of inhaled corticosteroids (800 µg budesonide daily) may have been too low to be sufficient. Two other large long term multicentre European studies of COPD will soon present the long term effects of a low to medium dosage of inhaled corticosteroids in mild COPD (800–1200 µg budesonide daily; Copenhagen City Lung Study) and a relatively high daily dose in severe COPD (1000 µg fluticasone; ISOLDE). This may help us to understand better the minimal daily dose of inhaled corticosteroids required to prevent progression of the decline in lung function in COPD.

The beneficial course of FEV₁ in patients treated with inhaled corticosteroids compared with placebo was not accompanied by a lower number of exacerbations. Bacterial superinfection is a common cause of acutely aggravating COPD. It might not be expected that inhaled corticosteroids protect the bronchial wall of the host against bacterial colonisation in patients with COPD. However, this result has to be treated with caution because the definition of exacerbation varied between the three studies in the meta-analysis (see table 1).

Several variables influenced the course of prebronchodilator FEV₁ independently. The regular use of both oral and inhaled β₂ agonists was related independently to an overall change in both prebronchodilator and postbronchodilator FEV₁ of +0.063 l/1/year after two years. This result strongly contrasts with the general opinion that regular use of β₂ agonists cannot delay the progression of COPD. However, the route of administration, dosages, and drug names of the β₂ agonists were not specified in the largest study. Our result therefore has to be interpreted with caution.

Contrary to others, the meta-analysis did not show a relationship between higher levels of IgE or airway reversibility and a better response to inhaled corticosteroids in COPD. As already mentioned, allergy was an exclusion criterion in two of the three studies. Also, subjects with reversible airway obstruction were excluded from the analysis. Both factors may explain the absence of an interaction effect of relatively low levels of IgE and airway reversibility on the response to inhaled corticosteroids. No other variables interacted with the effect of inhaled corticosteroids.

Up to now, smoking cessation has been shown to be the only intervention able to improve the FEV₁ of COPD patients, and is only published in abstract form. A daily dose of 1500 µg beclomethasone or 1600 µg budesonide was more effective than 800 µg inhaled corticosteroids are often sufficient to achieve disease control. In the light of our study we hypothesise that, in patients with moderate to severe COPD, differences in the type and site of inflammation in asthma and COPD might lead to the need for higher dosages of inhaled corticosteroids in COPD. In COPD the largely neutrophilic and lymphocytic inflammation seems to take place in the peripheral airways while in asthma the predominantly eosinophilic inflammation is located mainly in the central airways. These two considerations might explain the need for a higher dosage of inhaled corticosteroids in moderate to severe COPD compared with moderate asthma. If we consider the preliminary results of the EUROSCOP, the dosage of inhaled corticosteroids (800 µg budesonide daily) may have been too low to be sufficient. Two other large long term multicentre European studies of COPD will soon present the long term effects of a low to medium dosage of inhaled corticosteroids in mild COPD (800–1200 µg budesonide daily; Copenhagen City Lung Study) and a relatively high daily dose in severe COPD (1000 µg fluticasone; ISOLDE). This may help us to understand better the minimal daily dose of inhaled corticosteroids required to prevent progression of the decline in lung function in COPD.

The beneficial course of FEV₁ in patients treated with inhaled corticosteroids compared with placebo was not accompanied by a lower number of exacerbations. Bacterial superinfection is a common cause of acutely aggravating COPD. It might not be expected that inhaled corticosteroids protect the bronchial wall of the host against bacterial colonisation in patients with COPD. However, this result has to be treated with caution because the definition of exacerbation varied between the three studies in the meta-analysis (see table 1).

Several variables influenced the course of prebronchodilator FEV₁ independently. The regular use of both oral and inhaled β₂ agonists was related independently to an overall change in both prebronchodilator and postbronchodilator FEV₁ of +0.063 l/1/year after two years. This result strongly contrasts with the general opinion that regular use of β₂ agonists cannot delay the progression of COPD. However, the route of administration, dosages, and drug names of the β₂ agonists were not specified in the largest study. Our result therefore has to be interpreted with caution.

Contrary to others, the meta-analysis did not show a relationship between higher levels of IgE or airway reversibility and a better response to inhaled corticosteroids in COPD. As already mentioned, allergy was an exclusion criterion in two of the three studies. Also, subjects with reversible airway obstruction were excluded from the analysis. Both factors may explain the absence of an interaction effect of relatively low levels of IgE and airway reversibility on the response to inhaled corticosteroids. No other variables interacted with the effect of inhaled corticosteroids.

Up to now, smoking cessation has been shown to be the only intervention able to improve the FEV₁ of COPD patients, and is only published in abstract form. A daily dose of 1500 µg beclomethasone or 1600 µg budesonide was more effective than 800 µg inhaled corticosteroids are often sufficient to achieve disease control. In the light of our study we hypothesise that, in patients with moderate to severe COPD, differences in the type and site of inflammation in asthma and COPD might lead to the need for higher dosages of inhaled corticosteroids in COPD. In COPD the largely neutrophilic and lymphocytic inflammation seems to take place in the peripheral airways while in asthma the predominantly eosinophilic inflammation is located mainly in the central airways. These two considerations might explain the need for a higher dosage of inhaled corticosteroids in moderate to severe COPD compared with moderate asthma. If we consider the preliminary results of the EUROSCOP, the dosage of inhaled corticosteroids (800 µg budesonide daily) may have been too low to be sufficient. Two other large long term multicentre European studies of COPD will soon present the long term effects of a low to medium dosage of inhaled corticosteroids in mild COPD (800–1200 µg budesonide daily; Copenhagen City Lung Study) and a relatively high daily dose in severe COPD (1000 µg fluticasone; ISOLDE). This may help us to understand better the minimal daily dose of inhaled corticosteroids required to prevent progression of the decline in lung function in COPD.

The beneficial course of FEV₁ in patients treated with inhaled corticosteroids compared with placebo was not accompanied by a lower number of exacerbations. Bacterial superinfection is a common cause of acutely aggravating COPD. It might not be expected that inhaled corticosteroids protect the bronchial wall of the host against bacterial colonisation in patients with COPD. However, this result has to be treated with caution because the definition of exacerbation varied between the three studies in the meta-analysis (see table 1).


8 Dompeling E, Schayck CP van, Grunsven PM van, \textit{et al.} Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study. \textit{Am J Respir Crit Care Med} 1995;151:A463.


Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis


Thorax 1999 54: 7-14
doi: 10.1136/thx.54.1.7

Updated information and services can be found at:
http://thorax.bmj.com/content/54/1/7

These include:

References
This article cites 16 articles, 6 of which you can access for free at:
http://thorax.bmj.com/content/54/1/7#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Drugs: respiratory system (526)
Asthma (1782)
Clinical trials (epidemiology) (557)
Internet (104)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/